This tiny biotech caught fire in 2024. Can it sustain the momentum?
These two small-cap growth stocks could be ready to run.
Think globally with this high-yielding ETF.
Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate.
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for use in laboratories and point of...
The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.
NetworkNewsWire Editorial Coverage :Â On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type...
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Last year wasn't great for either stock, but that's no reason to ignore them.